PTIX

Protagenic Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website rotagenic.com
Employees(FY) -
ISIN US74365N2027

Performance

-12.14%

-31.3%

-43.68%

-47.29%

-24.69%

YTD

-61.16%

Profile

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Advanced Technical Analysis

Technical Analysis of PTIX 2025-01-31

The stock indicators suggest a predominantly bearish sentiment, with a Moving Average Score of 3 and a Technical Score of 3 indicating strong negative momentum, while the Oscillators Score of 50 reflects a neutral stance. Overall, the combined scores point to a cautious outlook for the stock, warranting careful consideration before making invest...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of PTIX

Stock Rank

Recent News & Updates

2024-11-04 19:12
Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million(Accesswire)
2024-10-28 21:27
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million(Yahoo Finance)
2024-06-24 18:53
PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q1 2024(Investorplace)
2024-05-21 20:12
Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders(Accesswire)
2024-04-30 20:38
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial(Accesswire)
2024-04-16 20:42
Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit(Accesswire)
2024-04-01 09:53
PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023(Investorplace)
2024-04-01 04:20
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results(Accesswire)
2024-03-26 20:42
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders(Accesswire)
2024-03-25 05:00
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call(Accesswire)
2024-03-20 20:41
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice(Accesswire)
2024-02-12 19:30
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders(Accesswire)
2023-12-11 18:30
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals(Yahoo Finance)
2023-10-12 21:00
Protagenic Therapeutics Announces Date of Annual Shareholder Meeting(Accesswire)
2023-09-25 20:18
Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114(Yahoo Finance)
2023-03-22 00:55
Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split(Yahoo Finance)
2022-04-25 20:15
Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th(Yahoo Finance)
2021-11-15 20:58
Protagenic Therapeutics Announces Third Quarter 2021 Results and Business Update(Yahoo Finance)
2021-08-29 21:15
Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET(Yahoo Finance)
2021-08-16 19:45
Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update(Yahoo Finance)
2021-07-23 04:21
Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial(Yahoo Finance)
2021-07-07 23:20
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021(Yahoo Finance)
2021-07-05 18:17
Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET(Yahoo Finance)
2021-06-22 21:35
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021(Yahoo Finance)
2021-06-15 21:15
Protagenic Therapeutics to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th(Yahoo Finance)
2021-04-29 03:06
Protagenic Therapeutics, Inc. Announces Closing of $13.2 Million Public Offering and Uplisting to Nasdaq(Yahoo Finance)
2021-04-26 08:58
Protagenic Therapeutics, Inc. Announces Nasdaq Uplisting andÂ Pricing of $13.2 Million Public Offering(Yahoo Finance)
2020-12-15 20:15
Dr. Maurizio Fava of Massachusetts General Hospital to Serve as Principal Investigator for PT00114 Clinical Trial(Yahoo Finance)
2020-09-08 00:10
Protagenic Therapeutics Completes $2.0 Million Convertible Note Financing(Yahoo Finance)

Page 1 of 1

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.